Eltrombopag Drugs Market Report 2026

The eltrombopag drugs market size has grown strongly in recent years. It will grow from $2.49 billion in 2025 to $2.71 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to limited availability of eltrombopag formulations, increasing prevalence of thrombocytopenia disorders, reliance on conventional therapies, growing hospital infrastructure, rising awareness among healthcare providers.

The eltrombopag drugs market size is expected to see strong growth in the next few years. It will grow to $3.77 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to development of new oral and suspension formulations, expansion of patient-friendly dosing options, increasing adoption in homecare settings, growth in online pharmacy distribution, rising research in combination therapies for thrombocytopenia. Major trends in the forecast period include rising adoption of eltrombopag tablets and oral suspensions, growing awareness of chronic immune thrombocytopenia and related disorders, expansion of hospital and retail pharmacy distribution networks, increasing use in hepatitis c-associated thrombocytopenia and severe aplastic anemia, development of flavored and patient-friendly oral formulations.

The rising prevalence of thrombocytopenia-related disorders is expected to drive the growth of the eltrombopag drugs market in the coming years. Thrombocytopenia-related disorders are medical conditions characterized by an abnormally low platelet count in the blood, which can result in increased bleeding, bruising, and impaired clot formation. The incidence of these disorders is increasing due to the growing prevalence of autoimmune diseases, where the immune system mistakenly attacks healthy platelets. Eltrombopag drugs help manage thrombocytopenia by stimulating platelet production through activation of the thrombopoietin receptor, thereby lowering the risk of bleeding complications. For example, according to the Centers for Disease Control and Prevention (CDC) in August 2024, the proportion of people with IgM antibodies indicating recent infection rose across all age groups from under 3% in 2022 to 10% by June 2024, with the most significant increase among children aged 5 to 9 years, rising from 15% to 40%. This growing prevalence of thrombocytopenia-related disorders is therefore supporting the expansion of the eltrombopag drugs market.

The increasing number of clinical trials is also expected to drive market growth. Clinical trials are research studies conducted in humans to assess the safety, efficacy, and outcomes of medical, surgical, or behavioral interventions. The number of clinical trials is rising due to the growing demand for new and effective therapies to address unmet medical needs and emerging health challenges. The expansion of clinical trials supports the development and validation of eltrombopag drugs, promoting their broader use in treating blood disorders. For instance, in December 2024, the Association of the British Pharmaceutical Industry reported that industry-sponsored clinical trials initiated in the United Kingdom increased from 411 in 2022 to 426 in 2023, while Phase III trial initiations grew by 16.5%, rising from 182 to 212. This trend in clinical research is fueling the growth of the eltrombopag drugs market.

Leading companies in the eltrombopag drugs market are focusing on innovations in drug formulations, such as next-generation oral forms, to improve patient compliance and therapeutic effectiveness. Oral formulations include medications taken by mouth, such as tablets, capsules, or liquid solutions, providing convenient and non-invasive drug delivery. For example, in May 2025, Camber Pharmaceuticals Inc., a US-based company, launched an AB-rated generic version of Promacta (eltrombopag) to increase access to cost-effective treatments for thrombocytopenia-related disorders. The product is available in tablet strengths of 12.5 mg, 25 mg, 50 mg, 75 mg, and 100 mg, along with an oral suspension of 12.5 mg/5 mL, designed for pediatric and adult patients who have difficulty swallowing tablets. These formulations contain eltrombopag olamine, a thrombopoietin receptor agonist that stimulates platelet production by activating the c-Mpl receptor on progenitor cells in the bone marrow.

Major companies operating in the eltrombopag drugs market are Novartis AG, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd, Intas Pharmaceuticals Ltd, Hetero Labs Limited, Dr. Reddy’s Laboratories Ltd, Alkem Laboratories Ltd, Granules India Ltd, Synthon BV, Metrochem API Pvt. Ltd, Taj Pharma India Ltd, Biophore India Pharmaceuticals Pvt. Ltd, Camber Pharmaceuticals Inc, Chunghwa Chemical Synthesis And Biotech Co. Ltd., Midas Pharma GmbH, Nuray Chemicals Private Limited, MSN Laboratories Private Limited., Aprazer Healthcare Private Limited., Eskay Healthcare Private Limited.

North America was the largest region in the eltrombopag drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eltrombopag drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the eltrombopag drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the eltrombopag drugs market by raising the cost of imported active pharmaceutical ingredients, tablets, and oral suspension components. Segments like hospital pharmacies and online pharmacies in regions such as North America and Europe, which heavily rely on imports, are most affected. This has increased treatment costs and created supply chain disruptions. On the positive side, tariffs have encouraged local manufacturing, formulation innovation, and greater investment in domestic production capabilities, potentially improving long-term product availability.

The eltrombopag drugs market research report is one of a series of new reports that provides eltrombopag drugs market statistics, including eltrombopag drugs industry global market size, regional shares, competitors with a eltrombopag drugs market share, detailed eltrombopag drugs market segments, market trends and opportunities, and any further data you may need to thrive in the eltrombopag drugs industry. This eltrombopag drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Eltrombopag drugs are medications used to increase platelet counts in patients with conditions such as chronic immune thrombocytopenia, hepatitis C-associated thrombocytopenia, and severe aplastic anemia. They function by stimulating the thrombopoietin receptor, which promotes platelet production in the bone marrow.

The primary forms of eltrombopag drugs are tablets and oral suspension. Eltrombopag tablets are oral medications that increase platelet counts in patients with thrombocytopenia by enhancing platelet production in the bone marrow. These drugs are used for various applications, including chronic immune thrombocytopenia, hepatitis C-associated thrombocytopenia, severe aplastic anemia, and more. They are distributed through multiple channels, such as hospital pharmacies, retail pharmacies, online pharmacies, and others, and serve a wide range of end users, including hospitals, clinics, homecare settings, and more.

The eltrombopag drugs market consists of sales of flavored suspension and tablets. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.